MiMedx Group (NASDAQ:MDXG) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded MiMedx Group (NASDAQ:MDXG) from a "buy" to a "hold" in its latest research report.
• Analysts have trimmed price targets (e.g., Craig Hallum, Citizens Jmp, Lake Street, Cantor Fitzgerald), but the consensus remains a "Moderate Buy" with an average target of $8.50 (six Buys, one Hold).
• MiMedx beat EPS estimates for the quarter (reported -$0.05 vs. est. -$0.07) but missed revenue ($58.99M vs. $65.80M); shares opened at $3.68 (up ~9.5%), market cap ≈ $547M, and institutional ownership is high (~79%).

MiMedx Group (NASDAQ:MDXG - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued on Saturday.

Several other research analysts also recently commented on the company. Craig Hallum decreased their price objective on MiMedx Group from $10.00 to $7.00 and set a "buy" rating on the stock in a research note on Friday, April 17th. Citigroup initiated coverage on shares of MiMedx Group in a report on Monday, February 23rd. They issued a "market outperform" rating for the company. Citizens Jmp decreased their target price on shares of MiMedx Group from $7.00 to $6.00 and set a "market outperform" rating on the stock in a research note on Thursday. Lake Street Capital lowered their price target on shares of MiMedx Group from $12.00 to $10.00 and set a "buy" rating on the stock in a report on Tuesday, January 20th. Finally, Cantor Fitzgerald dropped their price target on shares of MiMedx Group from $12.00 to $8.00 and set an "overweight" rating for the company in a research report on Tuesday, February 17th. Six analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, MiMedx Group has an average rating of "Moderate Buy" and an average target price of $8.50.

MiMedx Group Trading Up 9.5%

Shares of MDXG stock opened at $3.68 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.39 and a quick ratio of 3.92. The company has a market cap of $546.74 million, a price-to-earnings ratio of 18.40 and a beta of 1.47. MiMedx Group has a 1 year low of $3.03 and a 1 year high of $7.99. The firm has a fifty day moving average price of $4.12 and a 200-day moving average price of $5.63.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its earnings results on Wednesday, April 29th. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.02. MiMedx Group had a return on equity of 21.03% and a net margin of 7.88%.The company had revenue of $58.99 million for the quarter, compared to analysts' expectations of $65.80 million. As a group, equities analysts predict that MiMedx Group will post 0.08 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. First Light Asset Management LLC raised its position in shares of MiMedx Group by 89.5% during the third quarter. First Light Asset Management LLC now owns 3,652,952 shares of the company's stock valued at $25,498,000 after buying an additional 1,725,458 shares during the last quarter. Nantahala Capital Management LLC bought a new position in shares of MiMedx Group during the third quarter worth $10,237,000. Marshall Wace LLP boosted its position in shares of MiMedx Group by 864.9% during the fourth quarter. Marshall Wace LLP now owns 1,381,288 shares of the company's stock worth $9,351,000 after acquiring an additional 1,238,132 shares during the last quarter. Hillsdale Investment Management Inc. purchased a new position in MiMedx Group during the fourth quarter valued at $7,134,000. Finally, Disciplined Growth Investors Inc. MN grew its stake in MiMedx Group by 283.0% during the third quarter. Disciplined Growth Investors Inc. MN now owns 1,383,451 shares of the company's stock valued at $9,656,000 after acquiring an additional 1,022,202 shares in the last quarter. 79.15% of the stock is currently owned by institutional investors.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company's core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx's product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx's principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.